BladderBoneBrainBreastCervicalColonEsophagealKidneyLaryngealLeukemia CancerLiverLungLymphomaMouthOvarianPancreaticProstateRectalSkinTesticularThroatUterineHematology & OncologyPulmonologyPharmacyBladder CancerBone CancerBrain CancerBreast CancerCervical CancerColon CancerEsophageal CancerKidney CancerLaryngeal CancerLeukemiaLiver CancerLung CancerLymphoma CancerMouth CancerOvarian CancerPancreatic CancerProstate CancerRectal CancerSkin CancerTesticular CancerThroat CancerCancerUterine CancerGeneral HealthPrescription Drugs
HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, Sept. 29, 2015 (HealthDay News) -- In a recent study, patients with metastatic nonsquamous non-small-cell lung cancer treated with nivolumab lived an average of 12.2 months, while patients treated with docetaxel lived an average of 9.4 months. The results of this phase 3 trial were published online Sept. 27 in the New England Journal of Medicine to coincide with the 2015 European Cancer Congress, held from Sept. 25 to 29 in Vienna.
The patients in the trial had advanced nonsquamous, non-small-cell lung cancer and were current or former smokers. They were an average of 62 years old and received nivolumab after being treated with traditional chemotherapy.
At one year after treatment, 51 percent of the 292 patients treated with nivolumab were alive, compared with 39 percent of the 290 patients treated with docetaxel. At 18 months, overall survival was 39 percent among those treated with nivolumab and 23 percent among patients treated with docetaxel. Nivolumab was most effective for patients whose tumors expressed programmed death-ligand 1. In these patients, nivolumab resulted in longer overall and progression-free survival than docetaxel. Ten percent of patients treated with nivolumab had treatment-related adverse events of grade 3 or 4, compared with 54 percent of patients treated with docetaxel.
"It looks like we have a new treatment option for patients with metastatic lung cancer that progresses after standard chemotherapy," lead researcher Hossein Borghaei, D.O., chief of thoracic medical oncology at the Fox Chase Cancer Center in Philadelphia, told HealthDay.
The research was funded by Bristol-Myers Squibb, the manufacturer of nivolumab.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.
Updated on May 31, 2022
Read this Next
Other Trending Articles